Skip to main content
Egetis Therapeutics logo

Egetis Therapeutics — Investor Relations & Filings

Ticker · EGTX ISIN · SE0003815604 LEI · 549300RZCKGWRUBPMY22 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2024-03-29 AGM Information
Country SE Sweden
Listing ST EGTX

About Egetis Therapeutics

https://www.egetis.com/

Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious and rare diseases with significant unmet medical needs. The company's strategy centers on advancing drug candidates through late-stage clinical development to market approval. Its primary asset, Emcitate (tiratricol), is a first-in-class drug candidate in late-stage development for the treatment of Monocarboxylate Transporter 8 (MCT8) deficiency, a rare congenital disorder of thyroid hormone transport.

Recent filings

Filing Released Lang Actions
KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)
AGM Information Classification · 100% confidence The document is titled "KALLELSE TILL ÅRSSTÄMMA I EGETIS THERAPEUTICS AB (PUBL)" which translates to "NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)". It details the date, time, location, registration procedures (including deadlines based on the Euroclear Sweden AB share register), and the proposed agenda items for the meeting. The agenda includes items typical for an AGM, such as electing the chairman, approving the agenda, approving the annual report/financial statements (Item 8), electing the board and auditor (Items 11 & 12), and decisions regarding remuneration and incentive programs (Items 14, 16, 17). This content is characteristic of a formal notice calling shareholders to an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2024-03-29 Swedish
NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)
AGM Information Classification · 100% confidence The document is explicitly titled "NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)". It details the date, time, location, registration procedures, and the full agenda for the meeting. The agenda items (e.g., election of chairman, approval of remuneration, election of Board of Directors, resolution on incentive programs) are characteristic of materials distributed ahead of an Annual General Meeting (AGM). This directly corresponds to the AGM Information category.
2024-03-29 English
Audit Report / Information 2023
Audit Report / Information Classification · 95% confidence The document contains a detailed financial overview ('Finansiell översikt') with comparative figures for Q4 2023 vs Q4 2022 and full years 2023 vs 2022. It includes a CEO's statement ('VD har ordet'), updates on clinical trials (ReTRIACt, Triac Trial II), regulatory submissions (MAA to EMA), financing activities (new share issue and debt financing), and management changes. The content is comprehensive, covering operational, financial, and strategic developments over a reporting period, which strongly indicates a periodic financial report. Since it covers a full year (jan-dec) and a quarter (okt-dec), and is highly detailed, it aligns best with an Annual Report (10-K) or a comprehensive Interim/Quarterly Report (IR). Given the depth and the inclusion of full-year figures alongside quarterly ones, and the general nature of such comprehensive reports in non-US contexts often mirroring the detail of a 10-K, the most appropriate classification for a detailed periodic financial report is either 10-K or IR. Since the text explicitly shows both quarterly and full-year data, and is extensive (83k characters), it is more than just an 'Earnings Release' (ER). In the absence of an explicit '10-K' header, and given the Swedish language context (suggesting it might be a local equivalent or an 'Interim Report' if it's not the primary annual filing), 'IR' (Interim / Quarterly Report) is a strong candidate, although the inclusion of full-year data leans towards the annual filing structure. However, many companies issue a detailed annual report that functions as their 10-K equivalent. Given the structure and content covering the entire year's performance and outlook, it functions as the primary annual financial disclosure. If this were a US filer, it would be a 10-K. For a non-US filer providing full-year results, '10-K' is often used as the proxy for the main annual report, or 'IR' if it's specifically a half-year report. Since it covers the full year (jan-dec), I classify it as the Annual Report equivalent. FY 2023
2024-02-22 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 95% confidence The document provides a comprehensive review of the company's financial performance (including a table with 2023 vs 2022 data), operational updates, clinical trial progress, and management commentary. It is clearly a periodic financial report covering the full year 2023, as evidenced by the 'Financial overview' table and the detailed discussion of business milestones. It is not an earnings release (which is typically a short summary) nor a report publication announcement, as it contains substantive financial data and analysis. Q4 2023
2024-02-22 English
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
Environmental & Social Information Classification · 99% confidence The document is a press release announcing a specific corporate event: an exclusive license agreement between Egetis Therapeutics and Fujimoto Pharmaceutical Corporation regarding the drug Emcitate in Japan. It details financial terms (upfront payments, milestones) and future development plans. This type of announcement, which details a significant business transaction or partnership, is best classified as a general corporate update or regulatory filing that doesn't fit the more specific categories like Earnings Release (ER), Capital Update (CAP), or M&A (TAR, which usually implies a merger or takeover). Since it is a formal announcement of a material event, and the text itself is the announcement rather than a report attachment, it falls under the general 'Regulatory Filings' category (RNS) as a catch-all for significant, non-standard disclosures, or potentially a Capital/Financing Update (CAP) if the focus was purely on the financial structure, but the core is the licensing deal. Given the options, RNS is the most appropriate fallback for a material corporate transaction announcement that isn't explicitly covered by other codes like DIV, SHA, or TAR.
2023-11-10 English
Egetis ingår exklusivt licensavtal med Fujimoto för att utveckla och kommersialisera Emcitate i Japan
Regulatory Filings Classification · 95% confidence The document is a press release dated November 10, 2023, announcing that Egetis Therapeutics has entered into an exclusive license agreement with Fujimoto Pharmaceutical Corporation for the development and commercialization of Emcitate in Japan. The text details financial milestones (JPY 600 million), royalty structures, regulatory interactions (PMDA), and ongoing clinical trials (ReTRIACt). This content is a specific corporate announcement regarding a business development/licensing deal, which is a type of material event disclosure. It is not a full annual report (10-K), an earnings release (ER), a quarterly report (IR), or a proxy statement (DEF 14A). Since there is no specific category for 'Licensing Agreement' or 'Business Development', the most appropriate general category for a significant, non-financial-result-focused corporate announcement that is not covered by other specific codes (like DIRS, DIV, SHA, TAR) is the general regulatory filing fallback category, RNS (Regulatory Filings). However, given the nature of the announcement—a major strategic partnership and licensing deal—it often falls under broader corporate updates. Reviewing the definitions, 'Capital/Financing Update' (CAP) is for fundraising/capital structure changes, which this is not. 'M&A Activity' (TAR) is for mergers/takeovers, which this is not. Therefore, RNS serves as the best fit for a significant, non-standard corporate event disclosure.
2023-11-10 Swedish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.